drugset / Trial / NCT00004814
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
Phase 3
Completed
250 enrolled
National Center for Research Resources (NCRR)
University of Maryland · collab
RandomizedTreatment
Summary
OBJECTIVES: I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.
Timeline
- Start
- 1991-10
- Primary completion
- —
- Completion
- —
Outcome
Met primary endpoint
release “study that showed a significant reduction of MRI gadolinium-enhancing lesions (new active lesions) in patients treated with COPAXONE®.” tevapharm.com ↗
release “Treatment with COPAXONE® showed a significant reduction in T1 enhancing lesions as compared with placebo.” tevapharm.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glatiramer Acetate | Small molecule | — | Subcutaneous |